Sichuan Kelun Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.38

Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio is 0.38 for the year ending December 31, 2023, a -39.82% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.64, a -12.44% change year over year.
Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.73, a -14.95% change year over year.
Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.86, a 6.97% change year over year.
Sichuan Kelun Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.80, a 14.71% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

CEO	Mr. Sichuan Liu
IPO Date	June 3, 2010
Location	China
Headquarters	No.36 West Baihua Road
Employees	19,798
Sector	Health Care
Industries Pharmaceuticals

Description

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers IV solutions; injectable powder and small volume parenteral; oral preparation; intermediates and APIs; and peritoneal dialysis solutions. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Key trends

Past 5 years